Trial · NCT02586805
Adverse events180
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 180
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Placebo | 1 | 41 | 2 |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Lanadelumab (DX-2930) 150 mg Every 4 Weeks | 0 | 28 | 0 |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Lanadelumab (DX-2930) 300 mg Every 4 Weeks | 2 | 29 | 2 |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Lanadelumab (DX-2930) 300 mg Every 2 Weeks | 0 | 27 | 0 |
| other | Back pain | Musculoskeletal and connective tissue disorders | Placebo | 4 | 41 | 7 |
| other | Back pain | Musculoskeletal and connective tissue disorders | Lanadelumab (DX-2930) 150 mg Every 4 Weeks | 1 | 28 | 1 |
| other | Back pain | Musculoskeletal and connective tissue disorders | Lanadelumab (DX-2930) 300 mg Every 4 Weeks | 0 | 29 | 0 |
| other | Back pain | Musculoskeletal and connective tissue disorders | Lanadelumab (DX-2930) 300 mg Every 2 Weeks | 1 | 27 | 1 |
| other | Musculoskeletal pain | Musculoskeletal and connective tissue disorders | Placebo | 0 | 41 | 0 |
| other | Musculoskeletal pain | Musculoskeletal and connective tissue disorders | Lanadelumab (DX-2930) 150 mg Every 4 Weeks | 2 | 28 | 2 |
| other | Musculoskeletal pain | Musculoskeletal and connective tissue disorders | Lanadelumab (DX-2930) 300 mg Every 4 Weeks | 1 | 29 | 1 |
| other | Musculoskeletal pain | Musculoskeletal and connective tissue disorders | Lanadelumab (DX-2930) 300 mg Every 2 Weeks | 0 | 27 | 0 |
| other | Myalgia | Musculoskeletal and connective tissue disorders | Placebo | 0 | 41 | 0 |
| other | Myalgia | Musculoskeletal and connective tissue disorders | Lanadelumab (DX-2930) 150 mg Every 4 Weeks | 1 | 28 | 1 |
| other | Myalgia | Musculoskeletal and connective tissue disorders | Lanadelumab (DX-2930) 300 mg Every 4 Weeks | 0 | 29 | 0 |
| other | Myalgia | Musculoskeletal and connective tissue disorders | Lanadelumab (DX-2930) 300 mg Every 2 Weeks | 3 | 27 | 3 |
| other | Neck pain | Musculoskeletal and connective tissue disorders | Placebo | 1 | 41 | 1 |
| other | Neck pain | Musculoskeletal and connective tissue disorders | Lanadelumab (DX-2930) 150 mg Every 4 Weeks | 1 | 28 | 1 |
| other | Neck pain | Musculoskeletal and connective tissue disorders | Lanadelumab (DX-2930) 300 mg Every 4 Weeks | 0 | 29 | 0 |
| other | Neck pain | Musculoskeletal and connective tissue disorders | Lanadelumab (DX-2930) 300 mg Every 2 Weeks | 2 | 27 | 3 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02586805/events